Aclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: GlobeNewswire
ESKATA™ received FDA approval for the treatment of raised seborrheic keratoses (SKs) in December 2017 WAYNE, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that data will be presented from two Phase 3 clinical trials for ESKATA™ for the treatment of raised seborrheic keratoses (SKs). For the first time, detailed findings from SEBK-302 and SEBK-303 will be presented to attendees at the 2018 American Academy of Dermatology (AAD) Annual Meeting taking place February 16-20 in San Diego, California. ESKATA, formerly known as A-101 40% topical solution, is the first and only FDA-approved topical, non-invasive treatment for raised seborrheic keratoses. “These data highlight our robust clinical development program for ESKATA in which over 700 patients received treatment constituting the largest body of empirical research performed with respect to any potential raised SK treatment,” said Dr. N
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerPR Newswire
- Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 2/27/24 - Beat
ACRS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ACRS's page on the SEC website